There are 2789 resources available
714P - Prognostic factors in stage I seminoma: Data from the phase III, randomised TRial of Imaging and Surveillance in Seminoma Testis (TRISST)
Presenter: Elizabeth James
Session: ePoster Display
715P - Nivolumab in pretreated metastatic penile squamous cell carcinoma: Results of the penile cohort from the French AcSé prospective program
Presenter: Damien Pouessel
Session: ePoster Display
716TiP - IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy
Presenter: Thomas Powles
Session: ePoster Display
701P - Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) Tx: Results from IMPACT UC
Presenter: Mehmet Bilen
Session: ePoster Display
703P - Camrelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
Presenter: Nianzeng Xing
Session: ePoster Display
704P - Treatment patterns among patients with advanced urothelial carcinoma (aUC) in the USA
Presenter: Alicia Morgans
Session: ePoster Display
705P - Systematic literature review (SLR) and network meta-analysis (NMA) of first-line (1L) therapies for locally advanced/metastatic urothelial carcinoma (la/mUC)
Presenter: Lisa Bloudek
Session: ePoster Display
706P - Real-world study assessing physician rationale for initiating first-line (1L) immuno-oncology (IO) therapy for patients with advanced urothelial cancer (aUC)
Presenter: Mayank Ajmera
Session: ePoster Display